Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin
| العنوان: | Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin |
|---|---|
| المؤلفون: | Joan Brunet, Javier A. Menendez, Salvador Pedraza, Jordi Marruecos, Angel Izquierdo, Joaquim Bosch-Barrera, Manel Haro, Elisabet Cuyàs, Elia Sais, Noemí Cañete, Rut Porta |
| المصدر: | Oncotarget Oncotarget, 2016, vol. 7, núm. 22, p. 32006-32014 Articles publicats (D-CM) DUGiDocs – Universitat de Girona instname Recercat. Dipósit de la Recerca de Catalunya |
| بيانات النشر: | Impact Journals LLC, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Compassionate Use Trials, Male, Pathology, Lung Neoplasms, Time Factors, medicine.medical_treatment, Administration, Oral, Brain Edema, Lungs -- Cancer, Metastasis, Medicaments antineoplàstics, STAT3, chemistry.chemical_compound, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic agents, brain metastasis, Pulmons -- Càncer, Brain Neoplasms, Middle Aged, University hospital, Magnetic Resonance Imaging, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Research Paper, Silymarin, medicine.medical_specialty, Legasil, Silibinin, 03 medical and health sciences, Metàstasi, Internal medicine, medicine, Humans, Lung cancer, non-small cell lung cancer, Aged, silibinin, Chemotherapy, business.industry, Cancer, medicine.disease, Antineoplastic Agents, Phytogenic, Radiation therapy, 030104 developmental biology, chemistry, Silybin, Dietary Supplements, business, Tomography, X-Ray Computed, Brain metastasis |
| الوصف: | // Joaquim Bosch-Barrera 1, 2, 3 , Elia Sais 1 , Noemi Canete 2, 4 , Jordi Marruecos 2, 5 , Elisabet Cuyas 2, 6 , Angel Izquierdo 1, 2, 3 , Rut Porta 1, 2, 3 , Manel Haro 2, 3, 7 , Joan Brunet 1, 2, 3 , Salvador Pedraza 2, 3, 4 , Javier A. Menendez 2, 6 1 Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain 2 Girona Biomedical Research Institute (IDIBGi), Girona, Spain 3 Department of Medical Sciences, Medical School, University of Girona, Girona, Spain 4 Department of Radiology, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital, Girona, Spain 5 Department of Radiotherapy, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain 6 ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain 7 Department of Pneumology, Doctor Josep Trueta University Hospital, Girona, Spain Correspondence to: Joaquim Bosch-Barrera, email: jbosch@iconcologia.net Javier A. Menendez, email: jmenendez@idibgi.org ; jmenendez@iconcologia.net Keywords: non-small cell lung cancer, brain metastasis, silibinin, STAT3, Legasil Received: December 16, 2015 Accepted: February 21, 2016 Published: March 3, 2016 ABSTRACT Despite multimodal treatment approaches, the prognosis of brain metastases (BM) from non-small cell lung cancer (NSCLC) remains poor. Untreated patients with BM have a median survival of about 1 month, with almost all patients dying from neurological causes. We herein present the first report describing the response of BM from NSCLC patients to an oral nutraceutical product containing silibinin, a flavonoid extracted from the seeds of the milk thistle. We present evidence of how the use of the silibinin-based nutraceutical Legasil ® resulted in significant clinical and radiological improvement of BM from NSCLC patients with poor performance status that progressed after whole brain radiotherapy and chemotherapy. The suppressive effects of silibinin on progressive BM, which involved a marked reduction of the peritumoral brain edema, occurred without affecting the primary lung tumor outgrowth in NSCLC patients. Because BM patients have an impaired survival prognosis and are in need for an immediate tumor control, the combination of brain radiotherapy with silibinin-based nutraceuticals might not only alleviate BM edema but also prove local control and time for either classical chemotherapeutics with immunostimulatory effects or new immunotherapeutic agents such as checkpoint blockers to reveal their full therapeutic potential in NSCLC BM patients. New studies aimed to illuminate the mechanistic aspects underlying the regulatory effects of silibinin on the cellular and molecular pathobiology of BM might expedite the entry of new formulations of silibinin into clinical testing for progressive BM from lung cancer patients. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1949-2553 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94b38a29e39f9b6f6cffe6913c0d87e5Test http://europepmc.org/articles/PMC5077992Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....94b38a29e39f9b6f6cffe6913c0d87e5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19492553 |
|---|